NO20092278L - Mikroorganismer som baerere av nukleotid sekvenser kodende for antigener og protein toksiner, fremgangsmate for fremstilling og anvendelser derav - Google Patents

Mikroorganismer som baerere av nukleotid sekvenser kodende for antigener og protein toksiner, fremgangsmate for fremstilling og anvendelser derav

Info

Publication number
NO20092278L
NO20092278L NO20092278A NO20092278A NO20092278L NO 20092278 L NO20092278 L NO 20092278L NO 20092278 A NO20092278 A NO 20092278A NO 20092278 A NO20092278 A NO 20092278A NO 20092278 L NO20092278 L NO 20092278L
Authority
NO
Norway
Prior art keywords
microorganism
component
specific
nucleotide sequence
expression
Prior art date
Application number
NO20092278A
Other languages
English (en)
Norwegian (no)
Inventor
Joachim Fensterle
Ivaylo Gentschev
Ulf R Rapp
Werner Goebel
Original Assignee
Aeterna Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeterna Zentaris Gmbh filed Critical Aeterna Zentaris Gmbh
Publication of NO20092278L publication Critical patent/NO20092278L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
NO20092278A 2006-11-13 2009-06-12 Mikroorganismer som baerere av nukleotid sekvenser kodende for antigener og protein toksiner, fremgangsmate for fremstilling og anvendelser derav NO20092278L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86548406P 2006-11-13 2006-11-13
EP06123974A EP1921149A1 (en) 2006-11-13 2006-11-13 Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
US93914007P 2007-05-21 2007-05-21
PCT/EP2007/062237 WO2008058944A1 (en) 2006-11-13 2007-11-13 Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof

Publications (1)

Publication Number Publication Date
NO20092278L true NO20092278L (no) 2009-08-13

Family

ID=37846081

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092278A NO20092278L (no) 2006-11-13 2009-06-12 Mikroorganismer som baerere av nukleotid sekvenser kodende for antigener og protein toksiner, fremgangsmate for fremstilling og anvendelser derav

Country Status (29)

Country Link
US (1) US8669091B2 (sr)
EP (2) EP1921149A1 (sr)
JP (1) JP5479102B2 (sr)
KR (1) KR101505413B1 (sr)
CN (1) CN101595219B (sr)
AR (1) AR063795A1 (sr)
AT (1) ATE469971T1 (sr)
AU (1) AU2007321266B2 (sr)
BR (1) BRPI0719003A2 (sr)
CA (1) CA2669219A1 (sr)
CY (1) CY1111035T1 (sr)
DE (1) DE602007006985D1 (sr)
DK (1) DK2092067T3 (sr)
ES (1) ES2347019T3 (sr)
HR (1) HRP20100466T1 (sr)
IL (1) IL198736A0 (sr)
ME (1) ME01846B (sr)
MX (1) MX2009005038A (sr)
NO (1) NO20092278L (sr)
NZ (1) NZ576947A (sr)
PL (1) PL2092067T3 (sr)
PT (1) PT2092067E (sr)
RS (1) RS51416B (sr)
RU (1) RU2447145C2 (sr)
SI (1) SI2092067T1 (sr)
TW (1) TWI394834B (sr)
UA (1) UA94974C2 (sr)
WO (1) WO2008058944A1 (sr)
ZA (1) ZA200903022B (sr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2331271B1 (es) * 2007-06-29 2010-10-14 Universidad Del Pais Vasco Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas.
WO2009094006A2 (en) * 2007-10-25 2009-07-30 Wake Forest University Health Sciences Bordetella outer-membrane protein antigens and methods of making and using the same
EP2254902A1 (en) * 2008-02-05 2010-12-01 Æterna Zentaris GmbH Recombinant bacteria with e. coli hemolysin secretion system and increased expression and/or secretion of hlya, process of manufacturing and uses thereof
WO2010017383A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
KR101104077B1 (ko) * 2008-10-14 2012-01-11 건국대학교 산학협력단 Ｅｇｒ－１의 발현을 증가시키는 활성을 갖는 신규한 엔터로박테리아속에 속하는 신규균주 및 그 균주를 포함하는 조성물의 항암제로서의 용도
CN101480489B (zh) * 2008-12-03 2012-07-04 中国人民解放军第三军医大学 疟原虫环子孢子蛋白抗肿瘤增殖和迁移的新用途
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
GB2478734A (en) * 2010-03-15 2011-09-21 Sense Proteomic Ltd Auto-antibody biomarkers of prostate cancer
KR101229596B1 (ko) * 2010-05-13 2013-02-04 한국외국어대학교 연구산학협력단 사람 락토페리신 펩티드의 대장균 발현 플라스미드 및 그 용도
KR101907434B1 (ko) 2010-09-03 2018-10-12 발네바 오스트리아 게엠베하 C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도
CN103597078B (zh) * 2011-03-02 2016-12-14 富途锐基尼以色列有限公司 具有功能失调的t3ss蛋白的抗菌性转基因植物
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
EP2753345B1 (en) * 2011-09-06 2016-07-13 Agency For Science, Technology And Research Polypeptide vaccine
US11680273B2 (en) 2011-09-23 2023-06-20 Loma Linda University Treatment of autoimmune diseases
WO2013044177A2 (en) * 2011-09-23 2013-03-28 Loma Linda University Bacterial strains expressing methylase genes and uses thereof
EP2583975A1 (en) * 2011-10-21 2013-04-24 Heinrich-Heine-Universität Düsseldorf Agents and methods for the expression and secretion of peptides and proteins
WO2013076580A2 (en) * 2011-11-23 2013-05-30 Bioven 3 Limited Recombinant proteins and their therapeutic uses
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
WO2013151677A1 (en) 2012-04-02 2013-10-10 Broad Institute, Inc. Ddr2 mutations in cancer
JP6216371B2 (ja) * 2012-05-23 2017-10-18 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ＹｅｒｓｉｎｉａｐｅｓｔｉｓＦ１−Ｖ融合タンパク質を発現するＳａｌｍｏｎｅｌｌａＴｙｐｈｉＴｙ２１ａおよびその使用
JPWO2014017491A1 (ja) * 2012-07-26 2016-07-11 国立研究開発法人国立がん研究センター Ｃｅｐ５５遺伝子とｒｅｔ遺伝子との融合遺伝子
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2014140894A2 (en) * 2013-03-15 2014-09-18 Bioven 3 Limited Self-assembling synthetic proteins
EP2792686A1 (en) 2013-04-17 2014-10-22 Heinrich-Heine-Universität Düsseldorf Methods for the expression of peptides and proteins
DK2988762T3 (en) * 2013-04-25 2018-07-16 Vaximm Ag SALMONELLA-BASED VECTORS FOR CANCER IMMUNITY TARGET TARGETED WILMS 'TUMORGEN WT1
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN107001431B (zh) * 2014-05-21 2022-11-01 巴塞尔大学 基于细菌的蛋白质递送
EP3166637B1 (en) 2014-07-10 2020-01-29 The J. David Gladstone Institutes Compositions and methods for treating dengue virus infection
US12415995B2 (en) 2014-08-01 2025-09-16 Northwestern University Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders
WO2016019379A1 (en) * 2014-08-01 2016-02-04 Northwestern University Bacterial toxins and uses thereof as ras specific proteases
MA41217A (fr) * 2014-12-19 2017-10-24 Advaxis Inc Polythérapies ayant des souches de listeria recombinées
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
US11213577B2 (en) * 2015-04-28 2022-01-04 Albert Einstein College Of Medicine, Inc. Treatment of cancer using recall antigens delivered by attenuated bacteria
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017115798A1 (ja) 2015-12-28 2017-07-06 北海道公立大学法人 札幌医科大学 腫瘍抗原ペプチド
CN105601753A (zh) * 2016-02-22 2016-05-25 潍坊医学院 结核杆菌噬菌体双组份融合溶菌蛋白及其制备方法和应用
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
AU2017332854B2 (en) 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
CN107858430B (zh) * 2017-11-20 2019-01-04 武汉迈特维尔生物科技有限公司 一种用于诊断预示Her-2过表达型乳腺癌骨转移的基因诊断试剂盒
CN109593771B (zh) * 2018-07-27 2022-03-29 四川大学华西医院 一种人类map2k5第1100位碱基突变基因及其检测试剂盒
CN109486832B (zh) * 2018-12-29 2021-11-23 中国农业科学院棉花研究所 一种创建有限生长株型棉花的方法
JP7714465B2 (ja) * 2019-02-27 2025-07-29 ザ ジェネラル ホスピタル コーポレイション 弱毒化サルモネラ・チフィムリウム（Ｓａｌｍｏｎｅｌｌａ ｔｙｐｈｉｍｕｒｉｕｍ）を使用する良性神経系腫瘍の処置
CN110330548B (zh) * 2019-06-28 2021-03-09 哈尔滨医科大学 一种抗肿瘤多肽及其在制备抗肿瘤药物中的应用
CN110237240A (zh) * 2019-07-03 2019-09-17 上海市肺科医院 可溶性受体酪氨酸激酶sAxl在治疗结核病中的应用
WO2021026335A1 (en) * 2019-08-08 2021-02-11 The Trustees Of Indiana University Methods for identifying and treating urinary tract infections
WO2021030358A1 (en) 2019-08-12 2021-02-18 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
CN113694202B (zh) * 2020-06-29 2023-03-31 江苏省中医院 Ass1或bckdk抑制剂在制备治疗溃疡性结肠炎的药物中的应用
CA3198114A1 (en) * 2020-11-09 2022-05-12 Jung-Joon Min Salmonella strain for prevention and treatment of cancer and use thereof
WO2022225267A1 (ko) * 2021-04-19 2022-10-27 엠브릭스 주식회사 보툴리늄 독소 전위 도메인 및 엔도라이신을 포함하는 단백질 복합체 및 이를 포함하는 항균 조성물
CN117741161B (zh) * 2021-08-30 2026-07-07 河南中医药大学 Plekho2和npm3自身抗体在制备检测桥本甲状腺炎阴虚火旺证试剂盒中的应用
CN114921546B (zh) * 2022-05-13 2023-02-21 核工业总医院 circHIPK2作为乳腺癌生物标志物的应用
GB202209115D0 (en) * 2022-06-21 2022-08-10 Chain Biotechnology Ltd Compositions and methods
CN115877004B (zh) * 2022-08-09 2024-12-20 重庆大学 一种taok3抑制剂以及taok3及其抑制剂在调控天然免疫系统中的应用
WO2024054673A1 (en) * 2022-09-09 2024-03-14 Texas Tech University System Listeria monocytogenes as a vector for tumor-specific delivery of chemotherapeutic agents
CN115873774A (zh) * 2022-12-02 2023-03-31 无锡市南京大学锡山应用生物技术研究所 一种降解胞内肿瘤增殖蛋白的细菌
CN115976033B (zh) * 2022-12-14 2024-05-17 西南大学 瓜实蝇tssk1和tssk3基因及其应用
CN116254213B (zh) * 2022-12-15 2026-01-30 浙江大学杭州国际科创中心 一种低氧诱导分泌乳酸氧化酶的大肠杆菌工程菌及其应用
CN116344067B (zh) * 2023-01-17 2024-11-19 中山大学·深圳 流感易感标志物和基于该标志物的流感高危人群预测模型的构建方法与应用
KR102875606B1 (ko) * 2023-02-08 2025-10-24 충남대학교산학협력단 종양세포의 괴사를 유발하는 항암 살모넬라 균주 및 이를 포함하는 항암 조성물
JP2026506145A (ja) * 2023-02-17 2026-02-20 ピーディーシー ライン ファーマ 癌を治療するための形質細胞様樹状細胞
CN116875520B (zh) * 2023-07-12 2024-06-14 吉林农业大学 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用
EP4761753A2 (en) 2023-08-17 2026-06-24 Baccine Ltd. Genetically modified bacteria for multi-modal secretion of a neoantigen
CN117511967B (zh) * 2023-08-31 2024-07-02 中国科学院华南植物园 层出镰刀菌致病力相关基因FpAP1及其用途
CN118256561A (zh) * 2024-03-22 2024-06-28 徐州医科大学 靶向双激酶aurka/cdk7的疫苗在治疗实体瘤中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02170053A (ja) * 1988-12-23 1990-06-29 Meiji Seika Kaisha Ltd 微生物の検出方法及び装置
RU2092556C1 (ru) * 1995-08-29 1997-10-10 Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации Способ введения чужеродных генов в геномы грамотрицательных микроорганизмов, плазмидный вектор ркс47м для введения чужеродных генов в геномы грамотрицательных микроорганизмов, способ конструирования плазмидного вектора ркс47м
US6030624A (en) * 1996-08-16 2000-02-29 Uab Research Foundation Mucosal immunogens for novel vaccines
US6036953A (en) * 1996-11-29 2000-03-14 The General Hospital Corporation Heterologous antigens in live cell V. cholerae strains
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
DE60038622D1 (de) * 1999-10-20 2008-05-29 Univ Johns Hopkins Med Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure
GB0030067D0 (en) * 2000-12-11 2001-01-24 Univ Bristol Therapeutic agent
RU2216590C1 (ru) * 2002-02-26 2003-11-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Рекомбинантный аттенуированный штамм бактерий salmonella typhimurium t10/pkhbc - продуцент корового антигена вируса гепатита в
DE10208653A1 (de) 2002-02-28 2003-09-18 Medinnova Ges Med Innovationen Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren

Also Published As

Publication number Publication date
MX2009005038A (es) 2009-05-25
EP1921149A1 (en) 2008-05-14
KR101505413B1 (ko) 2015-03-25
JP2010508861A (ja) 2010-03-25
ES2347019T3 (es) 2010-10-22
ATE469971T1 (de) 2010-06-15
US20110287037A1 (en) 2011-11-24
PT2092067E (pt) 2010-08-31
AU2007321266B2 (en) 2012-11-15
JP5479102B2 (ja) 2014-04-23
KR20090092803A (ko) 2009-09-01
AR063795A1 (es) 2009-02-18
ME01846B (me) 2011-02-28
IL198736A0 (en) 2011-08-01
TW200837193A (en) 2008-09-16
BRPI0719003A2 (pt) 2013-12-17
HK1138314A1 (zh) 2010-08-20
RU2447145C2 (ru) 2012-04-10
TWI394834B (zh) 2013-05-01
CN101595219B (zh) 2016-01-27
US8669091B2 (en) 2014-03-11
ZA200903022B (en) 2010-03-31
PL2092067T3 (pl) 2010-11-30
RS51416B (sr) 2011-02-28
NZ576947A (en) 2011-12-22
RU2009122560A (ru) 2010-12-20
WO2008058944A1 (en) 2008-05-22
DE602007006985D1 (de) 2010-07-15
SI2092067T1 (sl) 2010-10-29
UA94974C2 (uk) 2011-06-25
CN101595219A (zh) 2009-12-02
CA2669219A1 (en) 2008-05-22
DK2092067T3 (da) 2010-09-06
EP2092067B1 (en) 2010-06-02
HRP20100466T1 (hr) 2010-10-31
CY1111035T1 (el) 2015-06-11
AU2007321266A1 (en) 2008-05-22
EP2092067A1 (en) 2009-08-26

Similar Documents

Publication Publication Date Title
MX2009005038A (es) Microorganismos como portadores de secuencias nucleotidicas que codifican para antigeno y toxinas proteinicas, procedimiento para elaboracion y usos de los mismos.
Koopman et al. Mechanisms and applications of bacterial sporulation and germination in the intestine
Guoyan et al. Bacillus subtilis spore surface display technology: a review of its development and applications
Hong et al. Multiplexed CRISPR-Cpf1-mediated genome editing in Clostridium difficile toward the understanding of pathogenesis of C. difficile infection
Sleytr et al. Bacterial S-layers
Lucas et al. The tyrosine decarboxylase operon of Lactobacillus brevis IOEB 9809: characterization and conservation in tyramine-producing bacteria
BR0008772B1 (pt) vetor de expressão, célula bacteriana ou fúngica cultivada, processos para expandir in vitro células hematopoiéticas e progenitores de células hematopoiéticas, e para detectar a presença de rna de ligando zalfa11 e de ligando zalfa 11 in vitro em uma amostra biológica.
Song et al. Chromosomal insertions in the Lactobacillus casei upp gene that are useful for vaccine expression
Preciado-Llanes et al. Evasion of MAIT cell recognition by the African Salmonella Typhimurium ST313 pathovar that causes invasive disease
JPS58126789A (ja) レースレオニンの製造法
JP2014083054A5 (sr)
Dinjaski et al. Swapping of phasin modules to optimize the in vivo immobilization of proteins to medium-chain-length polyhydroxyalkanoate granules in Pseudomonas putida
CA2923177A1 (en) Host cell modification with artificial endosymbionts
AU2025213625A1 (en) Auxotrophic strains of staphylococcus bacterium
Burenina et al. Small noncoding 6S RNAs of bacteria
Kitagawa et al. Biogenesis of Salmonella enterica serovar typhimurium membrane vesicles provoked by induction of PagC
BRPI0410562B8 (pt) proteína de veículo e seu método de produção em uma planta, ácido nucleico isolado, vetor de expressão e célula hospedeira
Sun et al. Nanoneedle‐Based Electroporation for Efficient Manufacturing of Human Primary Chimeric Antigen Receptor Regulatory T‐Cells
Babaer et al. Oligodeoxynucleotides ODN 2006 and M362 exert potent adjuvant effect through TLR-9/-6 synergy to exaggerate mammaglobin-A peptide specific cytotoxic CD8+ T lymphocyte responses against breast cancer cells
WO2003072789A3 (de) Mikroorganismen als träger von nukleotidsequenzen kodierend für zellantigene zur behandlung von tumoren
Otto et al. Activity of Staphylococcus epidermidis phenol-soluble modulin peptides expressed in Staphylococcus carnosus
Harris et al. Identification of Rhodococcus equi lipids recognized by host cytotoxic T lymphocytes
Stamm et al. Epithelial and mesenchymal cells in the bovine colonic mucosa differ in their responsiveness to Escherichia coli Shiga toxin 1
CN117616126A (zh) 可重新编程的tnpb多肽及其用途
CN109055398A (zh) 一种包含密码子优化cfp10基因的结核dna疫苗

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application